Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
19.96M | 19.63M | 14.92M | 9.83M | 26.54M | 11.24M | Gross Profit |
19.04M | 19.63M | -59.21M | 3.74M | 26.46M | 11.24M | EBIT |
-52.00M | -62.18M | -88.73M | -56.16M | -40.79M | -28.38M | EBITDA |
-49.46M | -57.12M | -85.89M | -51.99M | -40.11M | -27.93M | Net Income Common Stockholders |
-50.77M | -60.48M | -86.88M | -61.23M | -40.77M | -28.32M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
7.74M | 17.91M | 77.61M | 52.00M | 28.55M | 51.79M | Total Assets |
15.95M | 30.46M | 89.55M | 72.15M | 35.45M | 58.46M | Total Debt |
2.33M | 2.48M | 3.12M | 40.16M | 2.63M | 3.44M | Net Debt |
-5.42M | -15.43M | -74.48M | 15.97M | -25.92M | -48.34M | Total Liabilities |
52.62M | 58.37M | 63.02M | 101.28M | 9.43M | 8.31M | Stockholders Equity |
-36.66M | -27.91M | 26.53M | -49.26M | 11.63M | 35.76M |
Cash Flow | Free Cash Flow | ||||
-47.66M | -60.04M | -82.31M | -12.23M | -39.20M | -27.45M | Operating Cash Flow |
-47.56M | -59.92M | -81.18M | -7.57M | -37.33M | -27.01M | Investing Cash Flow |
418.00K | -123.00K | 72.41M | -32.56M | -1.87M | -440.00K | Financing Cash Flow |
-1.63M | 344.00K | 62.18M | 35.77M | 15.96M | 72.26M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
56 Neutral | $10.17M | 4.67 | -41.13% | ― | ― | ― | |
54 Neutral | $5.38B | 3.40 | -45.06% | 3.28% | 16.75% | -0.02% | |
49 Neutral | $9.42M | ― | -451.34% | ― | ― | -57.84% | |
48 Neutral | $46.38M | ― | -362.79% | ― | 32.45% | 39.31% | |
39 Underperform | $8.30M | ― | -285.79% | ― | ― | 23.65% | |
34 Underperform | $8.40M | ― | -126.03% | ― | -100.00% | -27.44% |
On June 10, 2025, Carisma Therapeutics received approval from a Nasdaq Hearings Panel to continue its listing on Nasdaq, with the listing being transferred to the Nasdaq Capital Market effective June 12, 2025. Despite previous non-compliance with Nasdaq’s listing rules, the company has been granted an extension until October 7, 2025, to meet specific conditions, including maintaining a minimum bid price and completing a strategic transaction, to ensure continued listing.
The most recent analyst rating on (CARM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Carisma Therapeutics stock, see the CARM Stock Forecast page.